CD46 and prostate carcinoma: Given that CD46 is becoming a credentialed target in mCRPC, an YS5-based antibody–drug conjugate is in multiple clinical trials (NCT03575819 and NCT05011188) with an established safety profile, and an YS5-PET imaging agent is in a first-in-human study (NCT05245006), our YS5-conjugated radioimmunotherapy has potential for rapid translation into the clinic for prostate cancer treatment.